Letibotulinumtoxina API Manufacturers

General Description:

Letibotulinumtoxina, identified by CAS number 1800016-51-6, is a notable compound with significant therapeutic applications. The aesthetic utility of botulinum toxin was discovered incidentally following its initial use in the treatment of facial spasmodic disorders in the early 1970s. The first aesthetic use of botulinum toxin was reported in 1989, when (Botox) was used as a treatment for facial asymmetry resulting from iatrogenic facial nerve damage. It was subsequently approved by the FDA in 1992 for use in aesthetic procedures and has since become one of the most popular cosmetic procedures worldwide. Letibotulinumtoxina is a type A botulinum neurotoxin produced from fermentation of _Clostridium botulinum_ strain CBFC26. It is a 900 kDa multimeric complex comprising a 150 kDa toxin, a 130 kDa non-toxic non-haemagglutinating protein, and various other haemagglutinins. Letibotulinumtoxina has been a market-leading cosmetic product in South Korea for a number of years and was more recently approved in the European Union. It was approved for use in Canada in June 2022 for the treatment of glabellar lines.

Indications:

This drug is primarily indicated for: Letibotulinumtoxina is indicated for the temporary improvement of the appearance of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients ≤65 years of age. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Metabolism:

Letibotulinumtoxina undergoes metabolic processing primarily in: As with other exogenously administered proteins, letibotulinumtoxina is expected to undergo non-specific enzymatic degradation to smaller peptides and amino acids. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.

Absorption:

The absorption characteristics of Letibotulinumtoxina are crucial for its therapeutic efficacy: Pharmacokinetic studies of letibotulinumtoxina are not feasible due to an extremely high affinity for its pre-synaptic cholinergic binding sites - as affinity is in the picomolar range, no detectable amount of toxin appears in the blood following administration. The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Pharmacodynamics:

Letibotulinumtoxina exerts its therapeutic effects through: The intramuscular injection of botulinum neurotoxin results in a dose-related muscle weakness resulting from the irreversible blockade of acetylcholine release from pre-synaptic vesicles. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Letibotulinumtoxina functions by: Letibotulinumtoxina, like other botulinum toxins, exerts its therapeutic effects via action directly on motor neurons. The toxin heavy chain mediates binding to surface receptors on nerve endings, after which the toxin is internalized via receptor-mediated endocytosis. The toxin light chain is subsequently translocated into the cytosol where it cleaves SNAP25, a cytosolic protein that forms a portion of the SNARE complex involved in vesicle fusion prior to exocytosis. The cleavage of SNAP25 prevents the formation of the SNARE complex, which subsequently prevents the exocytosis of acetylcholine into the neuromuscular junction, thereby inducing flaccid paralysis of the affected muscle(s). This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Toxicity:

Classification:

Letibotulinumtoxina belongs to the None, classified under the direct parent group Peptides. This compound is a part of the Organic Compounds, falling under the Organic Acids superclass, and categorized within the Carboxylic Acids and Derivatives class, specifically within the Amino Acids, Peptides, and Analogues subclass.

Categories:

Letibotulinumtoxina is categorized under the following therapeutic classes: Botulinum Toxins, Type A, Central Nervous System Depressants, Neuromuscular Agents, Neuromuscular Blocking Agents. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.